Pleural mesothelioma: is the surgeon still there?
Authors:
- 14 June 2018
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 29 (8) , 1710-1717
Abstract
MPM is a rare malignancy with some unique characteristics. Tumor biology is aggressive and prognosis is poor. Despite more knowledge on histology, tumor biology and staging, there is still a relevant discrepancy between clinical and pathologic staging resulting in difficult prediction of prognosis and treatment outcome, making treatment allocation more challenging than in most other malignancies. After years of nihilism in the late eighties, a period of activism started evaluating different treatment protocols combined with research driven mainly by academic centers; at the time, selection was based on histology and stage only. This period was important to gain knowledge about the disease. However, the interpretation of data was difficult since selection criteria and definitions varied substantially. Not surprisingly, until now there is no common agreement on best treatment even among specialists. Hence, a review of our current concepts is indicated and personalized treatment should become applicable in the future. Surgery was and still is an issue of debate. In principle, surgery is an effective approach as it allows macroscopic complete elimination of a tumor, which is relatively resistant to medical treatment. It helps to set the clock back and other therapies that have also just a limited effect can be applied sequentially before or after surgery. Furthermore, to date best long-term outcome is reported from surgical series in combination with other modalities. However, part of the community consider surgery associated with too high morbidity and mortality when balanced to the limited life expectancy. This criticism is understandable, since poor results after surgery are reported. The present article will review the indication for surgery and discuss the different procedures available for macroscopic complete resection– such as lung-preserving (extended) pleurectomy/decortication as well as extrapleural pneumonectomy to illustrate that “The surgeon is still there!”.Keywords
Funding Information
- Swiss National Science Foundation (Nr. PP00P3_133657, Nr. PP00P3_159269)
This publication has 47 references indexed in Scilit:
- Progress in Radical Surgery for Malignant Pleural MesotheliomaThe Open Cardiovascular and Thoracic Surgery Journal, 2013
- Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest GroupJournal of Thoracic Oncology, 2011
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility studyThe Lancet Oncology, 2011
- Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?European Respiratory Journal, 2011
- Efficacy and Safety of Tunneled Pleural Catheters in Adults with Malignant Pleural Effusions: A Systematic ReviewJournal of General Internal Medicine, 2010
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEuropean Respiratory Journal, 2009
- Local recurrence of tumor at sites of intervention in malignant pleural mesotheliomaLung Cancer, 2008
- The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma☆European Journal of Cardio-Thoracic Surgery, 2008
- Improved survival with VATS pleurectomy-decortication in advanced malignant mesotheliomaEuropean Journal of Surgical Oncology, 2005
- Postoperative Complications of Pulmonary Resection After Platinum-Based Induction Chemotherapy for Primary Lung CancerSurgery Today, 2003